Recent News

• 09.12.2025 - Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
• 09.05.2025 - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
• 08.25.2025 - HUTCHMED Announces Appointment of Acting Chief Executive Officer
• 08.20.2025 - HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
• 08.07.2025 - HUTCHMED Reports 2025 Interim Results
• 07.03.2025 - HUTCHMED to Announce 2025 Half-Year Financial Results
• 06.30.2025 - HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Recent Filings

• 09.05.2025 - EX-99.1 EX-99.1
• 09.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.25.2025 - EX-99.1 EX-99.1
• 08.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.20.2025 - EX-99.1 EX-99.1
• 08.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.03.2025 - EX-99.1 EX-99.1
• 07.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]